Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDCA in Newly Diagnosed CTX
NCT06260748Phase 3Withdrawn
- Sponsor
- Leadiant Biosciences
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of chenodeoxycholic acid in cerebrotendinous xanthomatosis (CTX), sponsored by Leadiant Biosciences. Planned start May 2024; status: withdrawn.
02
Drugs
chenodeoxycholic acid
03
Conditions
cerebrotendinous xanthomatosis (CTX)
Beyond the preview
Go deeper on NCT06260748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260748.